Annovis Bio Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases, announced it will present new findings on buntanetap at the 2025 Annual Meeting of the Parkinson Study Group, taking place Dec. 4–6 in San Diego. The presentation will expand on recent Phase 3 Parkinson’s biomarker results showing that patients with amyloid co-pathology experience more severe cognitive decline that is reversed by buntanetap, which also reduces tau biomarkers linked to disease progression.
Annovis will also debut a cross-study comparison of all completed trials, offering the most comprehensive view to date of cognitive outcomes across indications. This analysis underscores that patients with amyloid pathology achieve the greatest cognitive benefit, supporting the Company’s strategic path forward. The findings are particularly significant given the high prevalence of amyloid co-pathology in Parkinson’s disease patients, which can complicate treatment and accelerate cognitive decline.
The presentation at the Parkinson Study Group meeting, a leading forum for movement disorder research, provides a platform for Annovis to share its data with key opinion leaders and researchers. The company’s focus on addressing neurodegeneration in Alzheimer’s disease and Parkinson’s disease aligns with a growing need for therapies that target underlying disease mechanisms rather than just symptoms.
For more details, the full press release is available at https://ibn.fm/xiBPL. Investor news and updates relating to ANVS can be found in the company’s newsroom at https://ibn.fm/ANVS.
These developments come as Annovis continues to advance its clinical pipeline. The company’s ability to demonstrate cognitive benefit in a challenging patient population could position buntanetap as a potential disease-modifying therapy. The cross-study comparison provides a holistic view of the drug’s effects, which may be critical for regulatory discussions and future trial design.
Investors and researchers will be watching closely for the detailed data presented at the meeting, as it could influence the trajectory of Annovis’s development programs and the broader landscape of Parkinson’s disease treatment.
